Key Highlights

  • Shares rose 4.68% to USD 19.39 on relative Volume of 2.86.
  • The third-quarter net loss was USD 86.7 million versus USD 812.7 million.
  • Cash was USD 79.0 million and marketable securities were USD 402.6 million.
  • A new at-the-market agreement covers up to USD 150.0 million of stock.

Vor Biopharma (NASDAQ:VOR) shares traded at USD 19.39 on November 20, 2026, up 4.68%, with a relative volume at time of 2.86. The company has given no reason for the heavy trading. It filed its Quarterly Report and signed a new at-the-market sales agreement on October 30, so those events predate the session.

Vor Bio is a Delaware corporation based in Boston. It is a clinical-stage biopharmaceutical company developing a novel therapy for autoimmune diseases and has no approved products. In June 2025 it in-licensed telitacicept from RemeGen Co., Ltd., with exclusive rights to develop and commercialize it outside Greater China. Its fiscal year ends December 31.

The Third Quarter

The net loss was USD 86.7 million versus USD 812.7 million a year earlier. The loss per share was USD 1.45 versus USD 121.63, on 59,669,730 weighted-average shares versus 6,681,794.

Research and development expenses were USD 34.5 million versus USD 14.1 million, and general and administrative expenses were USD 23.9 million versus USD 14.0 million. Operating expenses and the operating loss were both USD 58.4 million versus USD 28.1 million. Interest income was USD 4.6 million versus USD 1.7 million.

Nine Months

The net loss was USD 369.1 million versus USD 2.42 billion, or USD 7.05 per share versus USD 378.11. Research and Development expenses were USD 78.0 million versus USD 302.3 million, and general and administrative expenses were USD 63.4 million versus USD 33.3 million. Operating expenses were USD 141.5 million versus USD 335.7 million, and interest income was USD 12.9 million versus USD 3.1 million.

Operating activities used USD 96.4 million versus USD 119.9 million. Net proceeds from common stock sold under the at-the-market agreement were USD 48.4 million versus USD 20.3 million.

Balance Sheet and Financing

Cash was USD 79.0 million versus USD 396.5 million at December 31, 2025, and marketable securities were USD 402.6 million versus USD 58.7 million. Total Assets were USD 496.3 million versus USD 464.1 million.

Liabilities were USD 633.5 million versus USD 628.4 million, and the stockholders' Deficit was USD 137.2 million versus USD 164.3 million. The accumulated deficit was USD 1,522.1 million, and 61,434,344 shares were outstanding at October 26.

On October 30 the company signed an at-the-market sales agreement with William Blair & Company, L.L.C. and RBC Capital Markets, LLC as sales agents, allowing sales of up to USD 150.0 million of common stock at a commission of up to 3.0% of gross proceeds. The earlier Stifel Facility expired by its terms after USD 125.0 million of shares had been sold.

Pipeline and Cash Runway

Vor Bio is developing telitacicept, a dual-target recombinant fusion protein that inhibits both BLyS (BAFF) and APRIL, in global Phase 3 trials for generalized myasthenia gravis and Sjögren's disease. It also runs a Phase 3 trial in ocular myasthenia gravis, called Upstream oMG. RemeGen keeps all rights to telitacicept in Greater China.

The company said its current operating plan lets its cash and marketable securities at September 30 fund operating and capital needs into early 2029.

What to Watch Next for Vor Biopharma

The company has given no reason for the November 20 trading, and its results and financing agreement came earlier. The reported record shows a much narrower loss than a year earlier, a lower cash balance and a stockholders' deficit. Its stated runway into early 2029 is the point to follow.